Experimental Therapeutics for Dystonia
Identifieur interne : 000166 ( Pmc/Curation ); précédent : 000165; suivant : 000167Experimental Therapeutics for Dystonia
Auteurs : H Jinnah [États-Unis] ; Ellen Hess [États-Unis]Source :
- Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics [ 1933-7213 ] ; 2008.
Abstract
Dystonia is a neurological syndrome characterized by excessive involuntary muscle contractions leading to twisting movements and unnatural postures. It has many different clinical manifestations, and many different causes. More than 3 million people worldwide suffer from dystonia, yet there are few broadly effective treatments. In the past decade, progress in research has advanced our understanding of the pathogenesis of dystonia to a point where drug discovery efforts are now feasible. There are several strategies that can be used to develop novel therapeutics for dystonia. Existing therapies have only modest efficacy, but may be refined and improved to increase benefits while reducing side effects. Identifying rational targets for drug intervention based on the pathogenesis of dystonia is another strategy. The surge in both basic and clinical research discoveries has provided insights at all levels including etiological, physiological and nosological, to enable such a targeted approach. The empirical approach to drug discovery is complementary to the rational approach whereby compounds are identified using a non-mechanistic strategy. [MD1] With the recent development of multiple animal models of dystonia, it is now possible to develop assays and perform drug screens on vast number of compounds. This multifaceted approach to drug discovery in dystonia will likely provide lead compounds that can then be translated for clinical use.
Url:
DOI: 10.1016/j.nurt.2008.01.001
PubMed: 18394563
PubMed Central: 2322876
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000166
Links to Exploration step
PMC:2322876Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Experimental Therapeutics for Dystonia</title>
<author><name sortKey="Jinnah, H A" sort="Jinnah, H A" uniqKey="Jinnah H" first="H" last="Jinnah">H Jinnah</name>
<affiliation wicri:level="2"><nlm:aff id="A1"> Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea> Department of Neurology, Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hess, Ellen J" sort="Hess, Ellen J" uniqKey="Hess E" first="Ellen" last="Hess">Ellen Hess</name>
<affiliation wicri:level="2"><nlm:aff id="A1"> Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea> Department of Neurology, Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A2"> Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea> Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">18394563</idno>
<idno type="pmc">2322876</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322876</idno>
<idno type="RBID">PMC:2322876</idno>
<idno type="doi">10.1016/j.nurt.2008.01.001</idno>
<date when="2008">2008</date>
<idno type="wicri:Area/Pmc/Corpus">000166</idno>
<idno type="wicri:Area/Pmc/Curation">000166</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Experimental Therapeutics for Dystonia</title>
<author><name sortKey="Jinnah, H A" sort="Jinnah, H A" uniqKey="Jinnah H" first="H" last="Jinnah">H Jinnah</name>
<affiliation wicri:level="2"><nlm:aff id="A1"> Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea> Department of Neurology, Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hess, Ellen J" sort="Hess, Ellen J" uniqKey="Hess E" first="Ellen" last="Hess">Ellen Hess</name>
<affiliation wicri:level="2"><nlm:aff id="A1"> Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea> Department of Neurology, Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A2"> Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea> Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</title>
<idno type="ISSN">1933-7213</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P2">Dystonia is a neurological syndrome characterized by excessive involuntary muscle contractions leading to twisting movements and unnatural postures. It has many different clinical manifestations, and many different causes. More than 3 million people worldwide suffer from dystonia, yet there are few broadly effective treatments. In the past decade, progress in research has advanced our understanding of the pathogenesis of dystonia to a point where drug discovery efforts are now feasible. There are several strategies that can be used to develop novel therapeutics for dystonia. Existing therapies have only modest efficacy, but may be refined and improved to increase benefits while reducing side effects. Identifying rational targets for drug intervention based on the pathogenesis of dystonia is another strategy. The surge in both basic and clinical research discoveries has provided insights at all levels including etiological, physiological and nosological, to enable such a targeted approach. The empirical approach to drug discovery is complementary to the rational approach whereby compounds are identified using a non-mechanistic strategy. [MD1] With the recent development of multiple animal models of dystonia, it is now possible to develop assays and perform drug screens on vast number of compounds. This multifaceted approach to drug discovery in dystonia will likely provide lead compounds that can then be translated for clinical use.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">101290381</journal-id>
<journal-id journal-id-type="pubmed-jr-id">33130</journal-id>
<journal-id journal-id-type="nlm-ta">Neurotherapeutics</journal-id>
<journal-title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</journal-title>
<issn pub-type="ppub">1933-7213</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">18394563</article-id>
<article-id pub-id-type="pmc">2322876</article-id>
<article-id pub-id-type="doi">10.1016/j.nurt.2008.01.001</article-id>
<article-id pub-id-type="manuscript">NIHMS45328</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Experimental Therapeutics for Dystonia</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Jinnah</surname>
<given-names>H. A.</given-names>
</name>
<xref rid="A1" ref-type="aff">*</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Hess</surname>
<given-names>Ellen J.</given-names>
</name>
<xref rid="A1" ref-type="aff">*</xref>
<xref rid="A2" ref-type="aff">†</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>*</label>
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287</aff>
<aff id="A2"><label>†</label>
Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21287</aff>
<author-notes><corresp id="FN1">Address correspondence to: Ellen J. Hess, Ph.D., Meyer Room 6-181, Department of Neurology, Johns Hopkins University, Baltimore MD, 21287; Ph.: 410-502-7511, Fax: 410-502-6737; E-mail: <email>ehess@jhmi.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>7</day>
<month>4</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="ppub"><month>4</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>1</day>
<month>4</month>
<year>2009</year>
</pub-date>
<volume>5</volume>
<issue>2</issue>
<fpage>198</fpage>
<lpage>209</lpage>
<abstract><p id="P2">Dystonia is a neurological syndrome characterized by excessive involuntary muscle contractions leading to twisting movements and unnatural postures. It has many different clinical manifestations, and many different causes. More than 3 million people worldwide suffer from dystonia, yet there are few broadly effective treatments. In the past decade, progress in research has advanced our understanding of the pathogenesis of dystonia to a point where drug discovery efforts are now feasible. There are several strategies that can be used to develop novel therapeutics for dystonia. Existing therapies have only modest efficacy, but may be refined and improved to increase benefits while reducing side effects. Identifying rational targets for drug intervention based on the pathogenesis of dystonia is another strategy. The surge in both basic and clinical research discoveries has provided insights at all levels including etiological, physiological and nosological, to enable such a targeted approach. The empirical approach to drug discovery is complementary to the rational approach whereby compounds are identified using a non-mechanistic strategy. [MD1] With the recent development of multiple animal models of dystonia, it is now possible to develop assays and perform drug screens on vast number of compounds. This multifaceted approach to drug discovery in dystonia will likely provide lead compounds that can then be translated for clinical use.</p>
</abstract>
<kwd-group><kwd>dystonia</kwd>
<kwd>animal models</kwd>
<kwd>drug discovery</kwd>
<kwd>pathogenesis</kwd>
<kwd>therapy</kwd>
</kwd-group>
<contract-num rid="NS1">R01 NS033592-11A2</contract-num>
<contract-sponsor id="NS1">National Institute of Neurological Disorders and Stroke : NINDS</contract-sponsor>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000166 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000166 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= JankovicV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:2322876 |texte= Experimental Therapeutics for Dystonia }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:18394563" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a JankovicV1
![]() | This area was generated with Dilib version V0.6.19. | ![]() |